Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.

[1]  N. Brünner,et al.  High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. , 1993, Cancer research.

[2]  V. Ellis,et al.  The Urokinase Receptor: Involvement in Cell Surface Proteolysis and Cancer Invasion , 1992, Annals of the New York Academy of Sciences.

[3]  J. Foekens,et al.  Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. , 1992, Cancer research.

[4]  D. Quinlan,et al.  Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. , 1992, Cancer research.

[5]  M. Duffy,et al.  Type‐1 plasminogen activator inhibitor in human breast carcinomas , 1992, International journal of cancer.

[6]  F. Blasi,et al.  In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion , 1991, The Journal of cell biology.

[7]  S. Steinberg,et al.  ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. , 1991, Cancer research.

[8]  F. Jänicke,et al.  Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast Cancer , 1991, Seminars in thrombosis and hemostasis.

[9]  K. Sugimachi,et al.  Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. , 1991, Cancer research.

[10]  F. Blasi,et al.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. , 1991, The American journal of pathology.

[11]  L. Liotta,et al.  Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation , 1991, Cell.

[12]  M. Duffy,et al.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. , 1990, Cancer research.

[13]  S. Rodenhuis,et al.  K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.

[14]  K. Danø,et al.  Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. , 1990, The Journal of biological chemistry.

[15]  M. Cubellis,et al.  Receptor‐mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI‐1. , 1990, The EMBO journal.

[16]  J. Sørensen,et al.  Prognostic factors in resected stages I and II adenocarcinoma of the lung. A multivariate regression analysis of 137 consecutive patients. , 1990, The Journal of thoracic and cardiovascular surgery.

[17]  S. Stacey,et al.  Plasminogen activator inhibitors: hormonally regulated serpins , 1990, Molecular and Cellular Endocrinology.

[18]  L. Lund,et al.  One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. , 1988, The Journal of biological chemistry.

[19]  D. Page,et al.  Lung cancer classification: The relationship of disease extent and cell type to survival in a clinical trials population , 1987, Journal of surgical oncology.

[20]  F. Blasi,et al.  Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors , 1987, The Journal of cell biology.

[21]  K. Danø,et al.  Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. , 1986, The Journal of biological chemistry.

[22]  K. Danø,et al.  immunocytochemical localization of urokinase-type plasminogen activator in lewis lung carcinoma , 1984, The Journal of cell biology.

[23]  G W Moore,et al.  Prognostic factors in surgically resected limited-stage, nonsmall cell carcinoma of the lung , 1984, The American journal of surgical pathology.

[24]  L. Ossowski,et al.  Antibodies to plasminogen activator inhibit human tumor metastasis , 1983, Cell.

[25]  K. Danø,et al.  The Plasminogen Activation System in Human Colon Cancer : Messenger RNA for the Inhibitor PAI-1 Is Located in Endothelial Cells in the Tumor , 2006 .

[26]  T Takahashi,et al.  Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. , 1993, Cancer research.

[27]  G. Murphy,et al.  Physiological mechanisms for metalloproteinase activation. , 1992, Matrix (Stuttgart, Germany). Supplement.

[28]  L. Kirkeby,et al.  Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. , 1991, The American journal of pathology.

[29]  A. Vaheri,et al.  Directed plasminogen activation at the surface of normal and malignant cells. , 1991, Advances in cancer research.

[30]  K. Danø,et al.  Immunohistochemical localization of urokinase- and tissue-type plasminogen activators in psoriatic skin. , 1987, The Journal of investigative dermatology.

[31]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.

[32]  S. Camiolo,et al.  Improved medium for extraction of plasminogen activator from tissue. , 1982, Preparative biochemistry.

[33]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .